Nie et al. previously reported that the polymorphism of CYP1A1 has a linkage with clinical outcome of NSCLC patients treated with EGFR-TKI (Nie et al., 2011a; Nie et al., 2011b). This evidence concerns the gene CYP1A1 and non-small cell lung carcinoma.